Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 99

1.

Suppression of inflammation in a mouse model of rheumatoid arthritis using targeted lipase-labile fumagillin prodrug nanoparticles.

Zhou HF, Yan H, Senpan A, Wickline SA, Pan D, Lanza GM, Pham CT.

Biomaterials. 2012 Nov;33(33):8632-40. doi: 10.1016/j.biomaterials.2012.08.005. Epub 2012 Aug 24.

2.

Antiangiogenic nanotherapy with lipase-labile Sn-2 fumagillin prodrug.

Pan D, Sanyal N, Schmieder AH, Senpan A, Kim B, Yang X, Hu G, Allen JS, Gross RW, Wickline SA, Lanza GM.

Nanomedicine (Lond). 2012 Oct;7(10):1507-19. doi: 10.2217/nnm.12.27. Epub 2012 Jun 18.

3.

Fumagillin prodrug nanotherapy suppresses macrophage inflammatory response via endothelial nitric oxide.

Zhou HF, Yan H, Hu Y, Springer LE, Yang X, Wickline SA, Pan D, Lanza GM, Pham CT.

ACS Nano. 2014 Jul 22;8(7):7305-17. doi: 10.1021/nn502372n. Epub 2014 Jun 24.

4.

alphaVbeta3-targeted copper nanoparticles incorporating an Sn 2 lipase-labile fumagillin prodrug for photoacoustic neovascular imaging and treatment.

Zhang R, Pan D, Cai X, Yang X, Senpan A, Allen JS, Lanza GM, Wang LV.

Theranostics. 2015 Jan 1;5(2):124-33. doi: 10.7150/thno.10014. eCollection 2015.

5.

Alphavbeta3-targeted nanotherapy suppresses inflammatory arthritis in mice.

Zhou HF, Chan HW, Wickline SA, Lanza GM, Pham CT.

FASEB J. 2009 Sep;23(9):2978-85. doi: 10.1096/fj.09-129874. Epub 2009 Apr 17.

6.

Antiangiogenic synergism of integrin-targeted fumagillin nanoparticles and atorvastatin in atherosclerosis.

Winter PM, Caruthers SD, Zhang H, Williams TA, Wickline SA, Lanza GM.

JACC Cardiovasc Imaging. 2008 Sep;1(5):624-34. doi: 10.1016/j.jcmg.2008.06.003.

7.

Anti-angiogenesis therapy in the Vx2 rabbit cancer model with a lipase-cleavable Sn 2 taxane phospholipid prodrug using α(v)β₃-targeted theranostic nanoparticles.

Pan D, Schmieder AH, Wang K, Yang X, Senpan A, Cui G, Killgore K, Kim B, Allen JS, Zhang H, Caruthers SD, Shen B, Wickline SA, Lanza GM.

Theranostics. 2014 Mar 11;4(6):565-78. doi: 10.7150/thno.7581. eCollection 2014.

8.

Fumagillin: an anti-infective as a parent molecule for novel angiogenesis inhibitors.

Lefkove B, Govindarajan B, Arbiser JL.

Expert Rev Anti Infect Ther. 2007 Aug;5(4):573-9. Review.

PMID:
17678422
9.

Three-dimensional MR mapping of angiogenesis with alpha5beta1(alpha nu beta3)-targeted theranostic nanoparticles in the MDA-MB-435 xenograft mouse model.

Schmieder AH, Caruthers SD, Zhang H, Williams TA, Robertson JD, Wickline SA, Lanza GM.

FASEB J. 2008 Dec;22(12):4179-89. doi: 10.1096/fj.08-112060. Epub 2008 Aug 12.

10.

Minute dosages of alpha(nu)beta3-targeted fumagillin nanoparticles impair Vx-2 tumor angiogenesis and development in rabbits.

Winter PM, Schmieder AH, Caruthers SD, Keene JL, Zhang H, Wickline SA, Lanza GM.

FASEB J. 2008 Aug;22(8):2758-67. doi: 10.1096/fj.07-103929. Epub 2008 Mar 24.

11.

FGFR1/PI3K/AKT signaling pathway is a novel target for antiangiogenic effects of the cancer drug fumagillin (TNP-470).

Chen GJ, Weylie B, Hu C, Zhu J, Forough R.

J Cell Biochem. 2007 Aug 15;101(6):1492-504.

PMID:
17295210
12.

Endothelial alpha(v)beta3 integrin-targeted fumagillin nanoparticles inhibit angiogenesis in atherosclerosis.

Winter PM, Neubauer AM, Caruthers SD, Harris TD, Robertson JD, Williams TA, Schmieder AH, Hu G, Allen JS, Lacy EK, Zhang H, Wickline SA, Lanza GM.

Arterioscler Thromb Vasc Biol. 2006 Sep;26(9):2103-9. Epub 2006 Jul 6.

13.

Generation of complexity in fungal terpene biosynthesis: discovery of a multifunctional cytochrome P450 in the fumagillin pathway.

Lin HC, Tsunematsu Y, Dhingra S, Xu W, Fukutomi M, Chooi YH, Cane DE, Calvo AM, Watanabe K, Tang Y.

J Am Chem Soc. 2014 Mar 19;136(11):4426-36. doi: 10.1021/ja500881e. Epub 2014 Mar 11.

14.

Fumagillin and fumarranol interact with P. falciparum methionine aminopeptidase 2 and inhibit malaria parasite growth in vitro and in vivo.

Chen X, Xie S, Bhat S, Kumar N, Shapiro TA, Liu JO.

Chem Biol. 2009 Feb 27;16(2):193-202. doi: 10.1016/j.chembiol.2009.01.006.

15.

Contact-facilitated drug delivery with Sn2 lipase labile prodrugs optimize targeted lipid nanoparticle drug delivery.

Pan D, Pham CT, Weilbaecher KN, Tomasson MH, Wickline SA, Lanza GM.

Wiley Interdiscip Rev Nanomed Nanobiotechnol. 2016 Jan-Feb;8(1):85-106. doi: 10.1002/wnan.1355. Epub 2015 Aug 21. Review.

16.

Dual-therapy with αvβ3-targeted Sn2 lipase-labile fumagillin-prodrug nanoparticles and zoledronic acid in the Vx2 rabbit tumor model.

Esser AK, Schmieder AH, Ross MH, Xiang J, Su X, Cui G, Zhang H, Yang X, Allen JS, Williams T, Wickline SA, Pan D, Lanza GM, Weilbaecher KN.

Nanomedicine. 2016 Jan;12(1):201-11. doi: 10.1016/j.nano.2015.10.003. Epub 2015 Oct 27.

17.

Fumagillin reduces adipose tissue formation in murine models of nutritionally induced obesity.

Lijnen HR, Frederix L, Van Hoef B.

Obesity (Silver Spring). 2010 Dec;18(12):2241-6. doi: 10.1038/oby.2009.503. Epub 2010 Jan 21.

18.

Nosema ceranae escapes fumagillin control in honey bees.

Huang WF, Solter LF, Yau PM, Imai BS.

PLoS Pathog. 2013 Mar;9(3):e1003185. doi: 10.1371/journal.ppat.1003185. Epub 2013 Mar 7.

19.

Antiparasitic activities of novel, orally available fumagillin analogs.

Arico-Muendel C, Centrella PA, Contonio BD, Morgan BA, O'Donovan G, Paradise CL, Skinner SR, Sluboski B, Svendsen JL, White KF, Debnath A, Gut J, Wilson N, McKerrow JH, DeRisi JL, Rosenthal PJ, Chiang PK.

Bioorg Med Chem Lett. 2009 Sep 1;19(17):5128-31. doi: 10.1016/j.bmcl.2009.07.029. Epub 2009 Jul 10.

20.

Stability of dicyclohexylamine and fumagillin in honey.

van den Heever JP, Thompson TS, Curtis JM, Pernal SF.

Food Chem. 2015 Jul 15;179:152-8. doi: 10.1016/j.foodchem.2015.01.111. Epub 2015 Jan 31.

PMID:
25722149

Supplemental Content

Support Center